Relevance of BRAFV600E Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer

Thyroid

Volumn 25, Issue 2, 2015, Pages 221-228

  Rossi, Martina ^a,b   Buratto, Mattia ^a   Tagliati, Federico ^a   Rossi, Roberta ^a,b   Lupo, Sabrina ^a,b   Trasforini, Giorgio ^b   Lanza, Giovanni ^a   Franceschetti, Paola ^b   Bruni, Stefania ^b   Degli Uberti, Ettore ^a,b   Zatelli, Maria Chiara ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; MOLECULAR MARKER; PROTEIN PATCHED; PROTEIN PATCHED 3; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; RET PROTEIN, HUMAN;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC VALUE; ECHOGRAPHY; FAMILY HISTORY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE REARRANGEMENT; GENETIC VARIABILITY; GOITER; HUMAN; LOBECTOMY; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE; THYROIDECTOMY; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYROID NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84922536622     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0338     Document Type: Article

References (27)

1. Ferraz C, Eszlinger M, Paschke R 2011 Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 96:2016-2026.
2. Keutgen XM, Filicori F, Fahey TJ 3rd 2013 Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev Mol Diag 13:613-623.
3. Freitas BC, Cerutti JMc 2010 Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol Cell Endocrinol 321:77-85.
4. Xing M, Haugen BR, Schlumberger M 2013 Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058-1069.
5. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L, Montanaro A, Pacini F 2010 Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 95:1365-1369.
6. Eszlinger M, Paschke R 2010 Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol 322:29-37.
7. Mehta V, Nikiforov YE, Ferris RL 2013 Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck 35:1499-1506.
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
9. Durante C, Costante G, Filetti S 2013 Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocr Relat Cancer 20:R141-R154.
10. Tuttle RM, Sabra MM 2013 Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. Oral Oncol 49:676-683.
11. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S; Papillary Thyroid Cancer Study Group 2010 Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 95:4882-4888.
12. Roti E, degli Uberti EC, Bondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 159:659-673.
13. Batawil N, Alkordy T 2014 Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules. Eur J Surg Oncol 40:182-186.
14. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 19:1159-1165.
15. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092-2098.
16. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC 2009 BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 161:467-473.
17. Rossi M, Buratto M, Bruni S, Filieri C, Tagliati F, Trasforini G, Rossi R, Beccati MD, degli Uberti EC, Zatelli MC 2012 Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol Metab 97:2354-2361.
18. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96:3390-3397.
19. Guerra A, Carrano M, Angrisani E, Puzziello A, Izzo G, Di Crescenzo V, Vatrella A, Vitale M 2014 Detection of RAS mutation by pyrosequencing in thyroid cytology samples. Int J Surg 12:S91-94.
20. Kabaker AS, Tublin ME, Nikiforov YE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Carty SE, Yip L 2012 Suspicious ultrasound characteristics predict BRAFV600Epositive papillary thyroid carcinoma. Thyroid 22:585-589.
21. Guerra A, Zeppa P, Bifulco M, Vitale M 2014 Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Thyroid 24:254-259.
22. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61:239-243.
23. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle M, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O Neill CJ, Sywak MS, Lam K, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501.
24. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982.
25. Schulten HJ, Salama S, Al-Ahmadi A, Al-Mansouri Z, Mirza Z, Al-Ghamdi K, Al-Hamour OA, Huwait E, Gari M, Al-Qahtani MH, Al-Maghrabi J 2013 Comprehensive sur-vey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Anticancer Res 33:4779-4784.
26. Marotta V, Guerra A, Sapio MR, Vitale M 2011 RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 165:499-507.
27. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 96:E916-919.